Role of A20 in cIAP-2 protection against tumor necrosis factor α (TNF-α)-mediated apoptosis in endothelial cells

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 3816-3833

  Guo, Shuzhen ^a,b   Messmer Blust, Angela F ^b   Wu, Jiaping ^b   Song, Xiaoxiao ^b   Philbrick, Melissa J ^b   Shie, Jue Lon ^b   Rana, Jamal S ^b   Li, Jian ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

A20; Apoptosis; cIAP 2; Endothelium; TNF

Indexed keywords

CASPASE 3; INHIBITOR OF APOPTOSIS PROTEIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; BIRC3 PROTEIN, HUMAN; CHROMONE DERIVATIVE; DNA BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MORPHOLINE DERIVATIVE; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINAE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CATTLE; CELLS, CULTURED; CHROMONES; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE EXPRESSION; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MORPHOLINES; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895503515     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15033816     Document Type: Article

References (60)

1. Winn, R.K.; Harlan, J.M. The role of endothelial cell apoptosis in inflammatory and immune diseases. J. Thromb. Haemost. 2005, 3, 1815-1824.
2. Badrichani, A.Z.; Stroka, D.M.; Bilbao, G.; Curiel, D.T.; Bach, F.H.; Ferran, C. Bcl-2 and bcl-xl serve an anti-inflammatory function in endothelial cells through inhibition of NF-κB. J. Clin. Investig. 1999, 103, 543-553.
3. He, K.L.; Ting, A.T. A20 inhibits tumor necrosis factor (TNF) α-induced apoptosis by disrupting recruitment of tradd and rip to the tnf receptor 1 complex in jurkat T cells. Mol. Cell. Biol. 2002, 22, 6034-6045.
4. Karsan, A.; Yee, E.; Harlan, J.M. Endothelial cell death induced by tumor necrosis factor-α is inhibited by the bcl-2 family member, a1. J. Biol. Chem. 1996, 271, 27201-27204.
5. Stehlik, C.; de Martin, R.; Kumabashiri, I.; Schmid, J.A.; Binder, B.R.; Lipp, J. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J. Exp. Med. 1998, 188, 211-216.
6. Lopez, J.; Meier, P. To fight or die-Inhibitor of apoptosis proteins at the crossroad of innate immunity and death. Curr. Opin. Cell Biol. 2010, 22, 872-881.
7. O'Riordan, M.X.; Bauler, L.D.; Scott, F.L.; Duckett, C.S. Inhibitor of apoptosis proteins in eukaryotic evolution and development: A model of thematic conservation. Dev. Cell 2008, 15, 497-508.
8. Lorick, K.L.; Jensen, J.P.; Fang, S.; Ong, A.M.; Hatakeyama, S.; Weissman, A.M. Ring fingers mediate ubiquitin-conjugating enzyme (e2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 1999, 96, 11364-11369.
9. Vince, J.E.; Wong, W.W.; Khan, N.; Feltham, R.; Chau, D.; Ahmed, A.U.; Benetatos, C.A.; Chunduru, S.K.; Condon, S.M.; McKinlay, M.; et al. Iap antagonists target ciap1 to induce TNFα-dependent apoptosis. Cell 2007, 131, 682-693.
10. LeBlanc, A.C. Natural cellular inhibitors of caspases. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27, 215-229.
11. Gyrd-Hansen, M.; Darding, M.; Miasari, M.; Santoro, M.M.; Zender, L.; Xue, W.; Tenev, T.; da Fonseca, P.C.; Zvelebil, M.; Bujnicki, J.M.; et al. Iaps contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis. Nat. Cell Biol. 2008, 10, 1309-1317.
12. Gyrd-Hansen, M.; Meier, P. Iaps: From caspase inhibitors to modulators of NF-κB, inflammation and cancer. Nat. Rev. 2010, 10, 561-574.
13. Petersen, S.L.; Peyton, M.; Minna, J.D.; Wang, X. Overcoming cancer cell resistance to smac mimetic induced apoptosis by modulating ciap-2 expression. Proc. Natl. Acad. Sci. USA 2010, 107, 11936-11941.
14. Wu, J.; Parungo, C.; Wu, G.; Kang, P.M.; Laham, R.J.; Sellke, F.W.; Simons, M.; Li, J. Pr39 inhibits apoptosis in hypoxic endothelial cells: Role of inhibitor apoptosis protein-2. Circulation 2004, 109, 1660-1667.
15. Opipari, A.W., Jr.; Hu, H.M.; Yabkowitz, R.; Dixit, V.M. The a20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol. Chem. 1992, 267, 12424-12427.
16. Jaattela, M.; Mouritzen, H.; Elling, F.; Bastholm, L. A20 zinc finger protein inhibits TNF and IL-1 signaling. J. Immunol. 1996, 156, 1166-1173.
17. Song, H.Y.; Rothe, M.; Goeddel, D.V. The tumor necrosis factor-inducible zinc finger protein a20 interacts with traf1/traf2 and inhibits NF-κB activation. Proc. Natl. Acad. Sci. USA 1996, 93, 6721-6725.
18. Ainbinder, E.; Amir-Zilberstein, L.; Yamaguchi, Y.; Handa, H.; Dikstein, R. Elongation inhibition by drb sensitivity-inducing factor is regulated by the a20 promoter via a novel negative element and NF-κB. Mol. Cell. Biol. 2004, 24, 2444-2454.
19. Ainbinder, E.; Revach, M.; Wolstein, O.; Moshonov, S.; Diamant, N.; Dikstein, R. Mechanism of rapid transcriptional induction of tumor necrosis factor α-responsive genes by NF-κB. Mol. Cell. Biol. 2002, 22, 6354-6362.
20. Evans, P.C.; Ovaa, H.; Hamon, M.; Kilshaw, P.J.; Hamm, S.; Bauer, S.; Ploegh, H.L.; Smith, T.S. Zinc-finger protein a20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J. 2004, 378, 727-734.
21. Lin, S.C.; Chung, J.Y.; Lamothe, B.; Rajashankar, K.; Lu, M.; Lo, Y.C.; Lam, A.Y.; Darnay, B.G.; Wu, H. Molecular basis for the unique deubiquitinating activity of the NF-κB inhibitor a20. J. Mol. Biol. 2008, 376, 526-540.
22. Wertz, I.E.; O'Rourke, K.M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D.L.; et al. De-ubiquitination and ubiquitin ligase domains of a20 downregulate NF-κB signalling. Nature 2004, 430, 694-699.
23. Daniel, S.; Arvelo, M.; Ferran, C. Overexpression of a20 in endothelial cells of vascularized grafts creates a protective barrier against TNF-and FAS-mediated apoptosis. Transplant. Proc. 2001, 33, 225.
24. Daniel, S.; Arvelo, M.B.; Patel, V.I.; Longo, C.R.; Shrikhande, G.; Shukri, T.; Mahiou, J.; Sun, D.W.; Mottley, C.; Grey, S.T.; et al. A20 protects endothelial cells from TNF-, FAS-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood 2004, 104, 2376-2384.
25. Dong, B.; Lv, G.; Wang, Q.; Wei, F.; Bellail, A.C.; Hao, C.; Wang, G. Targeting a20 enhances trail-induced apoptosis in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2012, 418, 433-438.
26. Hou, C.L.; Zhang, W.; Wei, Y.; Mi, J.H.; Li, L.; Zhou, Z.H.; Zeng, W.; Ying, D.J. Zinc finger protein a20 overexpression inhibits monocyte homing and protects endothelial cells from injury induced by high glucose. Genet. Mol. Res. 2011, 10, 1050-1059.
27. Hou, C.L.; Huang, Q.; Wei, Y.; Zhang, W.; Mi, J.H.; Ying, D.J.; Zhou, Z.H. Protein transduction domain-ha20 fusion protein protects endothelial cells against high glucose-induced injury. Genet. Mol. Res. 2012, 11, 1899-1908.
28. Gu, G.; Zhang, Y.; Guo, L. Ubiquitin e3 ligase a20 is required in degradation of microbial superantigens in vascular endothelial cells. Cell Biochem. Biophys. 2013, 66, 649-655.
29. Lee, E.G.; Boone, D.L.; Chai, S.; Libby, S.L.; Chien, M.; Lodolce, J.P.; Ma, A. Failure to regulate TNF-induced NF-κB and cell death responses in a20-deficient mice. Science 2000, 289, 2350-2354.
30. Hovelmeyer, N.; Reissig, S.; Xuan, N.T.; Adams-Quack, P.; Lukas, D.; Nikolaev, A.; Schluter, D.; Waisman, A. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur. J. Immunol. 2011, 41, 595-601.
31. Chng, H.W.; Camplejohn, R.S.; Stone, M.G.; Hart, I.R.; Nicholson, L.J. A new role for the anti-apoptotic gene a20 in angiogenesis. Exp. Cell Res. 2006, 312, 2897-2907.
32. Codd, J.D.; Salisbury, J.R.; Packham, G.; Nicholson, L.J. A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma. J. Pathol. 1999, 187, 549-555.
33. Hunter, A.M.; LaCasse, E.C.; Korneluk, R.G. The inhibitors of apoptosis (iaps) as cancer targets. Apoptosis 2007, 12, 1543-1568.
34. Dixit, V.M.; Green, S.; Sarma, V.; Holzman, L.B.; Wolf, F.W.; O'Rourke, K.; Ward, P.A.; Prochownik, E.V.; Marks, R.M. Tumor necrosis factor-α induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem. 1990, 265, 2973-2978.
35. Emmanuel, C.; Huynh, M.; Matthews, J.; Kelly, E.; Zoellner, H. TNF-α and TGF-β synergistically stimulate elongation of human endothelial cells without transdifferentiation to smooth muscle cell phenotype. Cytokine 2013, 61, 38-40.
36. Coornaert, B.; Carpentier, I.; Beyaert, R. A20: Central gatekeeper in inflammation and immunity. J. Biol. Chem. 2009, 284, 8217-8221.
37. Rothe, M.; Pan, M.G.; Henzel, W.J.; Ayres, T.M.; Goeddel, D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995, 83, 1243-1252.
38. Slowik, M.R.; Min, W.; Ardito, T.; Karsan, A.; Kashgarian, M.; Pober, J.S. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and-independent pathways. Lab. Investig. J. Tech. Methods Pathol. 1997, 77, 257-267.
39. Grey, S.T.; Arvelo, M.B.; Hasenkamp, W.; Bach, F.H.; Ferran, C. A20 inhibits cytokine-induced apoptosis and nuclear factor κB-dependent gene activation in islets. J. Exp. Med. 1999, 190, 1135-1146.
40. Ferran, C.; Stroka, D.M.; Badrichani, A.Z.; Cooper, J.T.; Wrighton, C.J.; Soares, M.; Grey, S.T.; Bach, F.H. A20 inhibits NF-κB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood 1998, 91, 2249-2258.
41. Arvelo, M.B.; Cooper, J.T.; Longo, C.; Daniel, S.; Grey, S.T.; Mahiou, J.; Czismadia, E.; Abu-Jawdeh, G.; Ferran, C. A20 protects mice from d-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 2002, 35, 535-543.
42. Hymowitz, S.G.; Wertz, I.E. A20: From ubiquitin editing to tumour suppression. Nat. Rev. 2010, 10, 332-341.
43. Grehan, J.F.; Levay-Young, B.K.; Benson, B.A.; Abrahamsen, M.S.; Dalmasso, A.P. α Gal ligation of pig endothelial cells induces protection from complement and apoptosis independently of NF-κB and inflammatory changes. Am. J. Transplant. 2005, 5, 712-719.
44. Conte, D.; Holcik, M.; Lefebvre, C.A.; Lacasse, E.; Picketts, D.J.; Wright, K.E.; Korneluk, R.G. Inhibitor of apoptosis protein ciap2 is essential for lipopolysaccharide-induced macrophage survival. Mol. Cell. Biol. 2006, 26, 699-708.
45. Conze, D.B.; Albert, L.; Ferrick, D.A.; Goeddel, D.V.; Yeh, W.C.; Mak, T.; Ashwell, J.D. Posttranscriptional downregulation of c-iap2 by the ubiquitin protein ligase c-iap1 in vivo. Mol. Cell. Biol. 2005, 25, 3348-3356.
46. Yamaguchi, N.; Oyama, M.; Kozuka-Hata, H.; Inoue, J. Involvement of a20 in the molecular switch that activates the non-canonical NF-κB pathway. Sci. Rep. 2013, 3, 2568.
47. Kingeter, L.M.; Schaefer, B.C. Malt1 and ciap2-malt1 as effectors of NF-κB activation: Kissing cousins or distant relatives? Cell. Signal. 2010, 22, 9-22.
48. Li, X.; Yang, Y.; Ashwell, J.D. TNF-RII and c-iap1 mediate ubiquitination and degradation of TRAF2. Nature 2002, 416, 345-347.
49. Zhao, X.; Bausano, B.; Pike, B.R.; Newcomb-Fernandez, J.K.; Wang, K.K.; Shohami, E.; Ringger, N.C.; DeFord, S.M.; Anderson, D.K.; Hayes, R.L. TNF-α stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures. J. Neurosci. Res. 2001, 64, 121-131.
50. Bozkurt, B.; Torre-Amione, G.; Warren, M.S.; Whitmore, J.; Soran, O.Z.; Feldman, A.M.; Mann, D.L. Results of targeted anti-tumor necrosis factor therapy with etanercept (enbrel) in patients with advanced heart failure. Circulation 2001, 103, 1044-1047.
51. Deswal, A.; Bozkurt, B.; Seta, Y.; Parilti-Eiswirth, S.; Hayes, F.A.; Blosch, C.; Mann, D.L. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99, 3224-3226.
52. Mann, D.L.; McMurray, J.J.; Packer, M.; Swedberg, K.; Borer, J.S.; Colucci, W.S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the randomized etanercept worldwide evaluation (renewal). Circulation 2004, 109, 1594-1602.
53. Setoguchi, S.; Schneeweiss, S.; Avorn, J.; Katz, J.N.; Weinblatt, M.E.; Levin, R.; Solomon, D.H. Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am. Heart J. 2008, 156, 336-341.
54. Solomon, D.H.; Curtis, J.R.; Saag, K.G.; Lii, J.; Chen, L.; Harrold, L.R.; Herrinton, L.J.; Graham, D.J.; Kowal, M.K.; Kuriya, B.; et al. Cardiovascular risk in rheumatoid arthritis: Comparing TNF-α blockade with nonbiologic dmards. Am. J. Med. 2013, 126, 730e9-730e17.
55. Solomon, D.H.; Rassen, J.A.; Kuriya, B.; Chen, L.; Harrold, L.R.; Graham, D.J.; Lewis, J.D.; Lii, J.; Liu, L.; Griffin, M.R.; et al. Heart failure risk among patients with rheumatoid arthritis starting a tnf antagonist. Ann. Rheum. Dis. 2013, 72, 1813-1818.
56. Kotyla, P.J.; Owczarek, A.; Rakoczy, J.; Lewicki, M.; Kucharz, E.J.; Emery, P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: Assessment of heart function by echocardiography, endothelin 1, interleukin 6, and nt-pro brain natriuretic peptide. J. Rheumatol. 2012, 39, 701-706.
57. Wu, G.; Luo, J.; Rana, J.S.; Laham, R.; Sellke, F.W.; Li, J. Involvement of COX-2 in VEGF-induced angiogenesis via p38 and jnk pathways in vascular endothelial cells. Cardiovasc. Res. 2006, 69, 512-519.
58. Pan, C.; Lou, L.; Huo, Y.; Singh, G.; Chen, M.; Zhang, D.; Wu, A.; Zhao, M.; Wang, S.; Li, J. Salvianolic acid B and tanshinone IIA attenuate myocardial ischemia injury in mice by no production through multiple pathways. Ther. Adv. Cardiovasc. Dis. 2011, 5, 99-111.
59. Jin, Y.; Wu, J.; Song, X.; Song, Q.; Cully, B.L.; Messmer-Blust, A.; Xu, M.; Foo, S.Y.; Rosenzweig, A.; Li, J. RTEF-1, an upstream gene of hypoxia-inducible factor-1α, accelerates recovery from ischemia. J. Biol. Chem. 2011, 286, 22699-22705.
60. Wu, G.; Mannam, A.P.; Wu, J.; Kirbis, S.; Shie, J.L.; Chen, C.; Laham, R.J.; Sellke, F.W.; Li, J. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: Role of VEGF. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H2420-H2429.